Track 1: Recommendations for Medical and Pharmacy Directors
Track 2: Recommendations for Care Managers

• Release date: November 15, 2011
• Expiration date: May 15, 2013
• Estimated time to complete activity: 1.0 hours for Track 1; 1.0 hours for Track 2; 2.0 hours total
• Compatible with (IE 6 and up, Firefox, Safari)

Target Audience

This activity has been designed to meet the educational needs of medical directors, pharmacy directors, clinical pharmacists, quality directors, registered nurses, as well as network physicians affiliated with various managed care organizations.

Statement of Need/Program Overview

Managed care professionals and affiliated clinicians involved in the management of and direct care for patients at risk for thromboembolic disorders are routinely challenged with multiple sets of anticoagulation guidelines and protocols specific to their individual hospital, anticoagulation clinic, and/or third party payer settings. This can lead to unexpected barriers to care, disrupted communication between caregivers, and inconsistency in the delivery of care. Evidence-based practices and consistent guidelines for screening, preventing, diagnosing, tracking, and treating thromboembolic disorders are needed, especially for patients at higher risk, to ensure that these practices are routinely applied by health care professionals in all settings.

Managed care organizations are in an excellent position to collaborate in the management of thromboembolic disorders. Managed care professionals and all members of a patient care team need to learn how to adapt their current approach and roles as providers to implement new treatment regimens that emphasize a more convenient and patient-centered approach for anticoagulation therapy.

Educational Objectives (Track 1)
After completing this activity, the participant should be better able to:

• Apply evidence-based clinical practice guidelines for thromboprophylaxis in atrial fibrillation
• Evaluate recent advances in thromboprophylactic therapy including patient risks and benefits of emerging anticoagulants compared with standard treatments
• Provide appropriate care and counsel for patients and their families
• Provide accurate and appropriate counsel as part of the treatment team

Educational Objectives (Track 2)
After completing this activity, the participant should be better able to:

• Employ managed care strategies that incorporate existing and evolving therapies into treatment guidelines
• Personalize the managed care implementation processes to improve outcomes for patients at risk for thromboembolic events
• Provide appropriate care and counsel for patients and their families
• Provide accurate and appropriate counsel as part of the treatment team

Distinguished Faculty (Track 1)

Jeffrey D. Dunn, PharmD, MBA Formulary and Contract Manager SelectHealth, Inc. Click here for biography

James B. Groce III, PharmD Professor of Pharmacy Practice Campbell University School of Pharmacy Clinical Assistant Professor of Medicine University of North Carolina School of Medicine Click here for biography

Distinguished Faculty (Track 2)

James B. Groce III, PharmD Professor of Pharmacy Practice Campbell University School of Pharmacy Clinical Assistant Professor of Medicine University of North Carolina School of Medicine Click here for biography

Robert T. Weibert, PharmD Associate Professor University of California San Diego School of Medicine Click here for biography

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Impact Education, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement (Per Track)
The Annenberg Center for Health Sciences at Eisenhower designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

	The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation (Per Track)
The Annenberg Center for Health Sciences at Eisenhower designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

• Track 1 Universal Activity Number: 0797-9999-11-017-H04-P
• Track 2 Universal Activity Number: 0797-9999-11-018-H04-P

Type of Activity
Knowledge-based

Nursing Continuing Education

Accreditation Statement

	Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation (Per Track)
A maximum of 1.0 contact hours may be earned for successful completion of this activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflicts of Interest
The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Method of Participation and Request for Credit
There are no fees for participating in and receiving CME/CE credit for this activity. During the period November 15, 2011, through May 15, 2013, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the online post-test, with a passing score of 70% or better; 4) complete the online evaluation form. Upon successful completion of post-test and evaluation, you will have access to an immediate online certificate.

Discloser of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Impact Education, LLC, and Bristol-Myers Squibb do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The Annenberg Center, PIM, Impact Education, LLC, and Bristol-Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Media
Internet

Fee Information
There is no fee for this educational activity.